ESBRIET

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug ESBRIET contains one active pharmaceutical ingredient (API):

1	Pirfenidone UNII D7NLD2JX7U - PIRFENIDONE
	Pirfenidone attenuates fibroblast proliferation, production of fibrosis-associated proteins and cytokines, and the increased biosynthesis and accumulation of extracellular matrix in response to cytokine growth factors. Pirfenidone is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF).
	Read more about Pirfenidone

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ESBRIET Hard capsule	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AX05	Pirfenidone	L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AX Other immunosuppressants
Discover more medicines within L04AX05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11136D, 11406H, 11410M
BR	Câmara de Regulação do Mercado de Medicamentos	529216090026702
CA	Health Products and Food Branch	02393751, 02464489, 02464500
EE	Ravimiamet	1518870, 1518881, 1518892, 1744332, 1744343, 1744354, 1744365, 1744387, 1750801, 1750812, 1750823, 1750834, 1750845, 1750856, 1750867, 1761487
ES	Centro de información online de medicamentos de la AEMPS	111667016, 111667018
FI	Lääkealan turvallisuus- ja kehittämiskeskus	383837, 446921, 559816
FR	Base de données publique des médicaments	66527665, 66673182
GB	Medicines & Healthcare Products Regulatory Agency	346226, 346233, 346238
HK	Department of Health Drug Office	64288, 67135, 67136
IE	Health Products Regulatory Authority	88389, 88864, 88869, 89001
IL	מִשְׂרַד הַבְּרִיאוּת	8450, 8486
LT	Valstybinė vaistų kontrolės tarnyba	1059260, 1059261, 1059262, 1083132, 1083133, 1083134, 1083135, 1083136, 1083137, 1083138, 1083219, 1083220, 1083221, 1083222, 1083223, 1083224, 1083235, 1083236, 1085551, 1085552
NL	Z-Index G-Standaard, PRK	107387, 146765, 146773
NZ	Medicines and Medical Devices Safety Authority	17627, 18789, 18790, 18791
PL	Rejestru Produktów Leczniczych	100299639, 100388260, 100388277, 100388283
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W64377001, W64378001, W64379001
SG	Health Sciences Authority	15124P, 15600P, 15601P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699505091228, 8699505091235
US	FDA, National Drug Code	50242-121, 50242-122, 50242-123
ZA	Health Products Regulatory Authority	50/32.16/1168